摘要
Next-generationsequencing(NGS)hasbeenrapidlyintegratedintomolecularpathology,dramaticallyincreasingthebreadthgenomicofinformationavailabletooncologistsandtheirpatients.Thisreviewwillexplorethewaysinwhichthisnewtechnologyiscurrentlyappliedtobolstercareforpatientswithsolidtumorsandhematologicalmalignancies,focusingonpracticesandguidelinesforassessingthetechnicalvalidityandclinicalutilityofDNAvariantsidentifiedduringclinicalNGSoncologytesting.
出版日期
2016年01月11日(中国期刊网平台首次上网日期,不代表论文的发表时间)